Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.21M
Average 0.22M
EPRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 113.8% from a year ago
Cash & equivalents stood at $58.69M at the end of Q1 FY2026, up 113.8% from a year earlier and down 27.1% from the prior quarter. Over 3 fiscal years it compounded at +48.2% a year.
Context
- Cash & equivalents amounted to 40.2% of total assets at the end of Q1 FY2026, down 53.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +113.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 80.56M USD
- Year-over-year change
- +143.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.56M | +143.4% |
| FY2024 | 2024-12-31 | 33.1M | +127.3% |
| FY2023 | 2023-12-31 | 14.56M | — |
| FY2022 | 2022-12-31 | 24.73M | +18.4% |
| FY2021 | 2021-12-31 | 20.89M | — |
Cash & Equivalents vs competitors
How EPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +113.8% is the 3rd highest of 10, against a peer median of +2.8%.
- Cash & equivalents amounts to 40.2% of total assets for EPRX, versus a peer median of 39.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $134.71M USD | +203.3% | +61.3% | 95.5% | |
| Mar 2026 | $118.64M USD | -34.2% | +5.5% | 41.1% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $62.44M USD | +135.6% | +44.6% | 63.3% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $58.69M USD | +113.8% | +48.2% | 40.2% |
| Mar 2026 | $44.65M USD | +16.7% | -47.9% | 55.8% | |
| Mar 2026 | $28.37M USD | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $14.74M USD | -83.9% | +27.2% | 7.7% | |
| Mar 2026 | $14.63M USD | -56.0% | -52.4% | 8.2% | |
| Mar 2026 | $138.6K USD | -97.5% | — | 4.2% | |
| Peer median (excluding EPRX) | — | +2.8% | +13.1% | 39.9% | |
Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.89M | 24.73M | 14.56M | 33.1M | 80.56M |
| Short-term Investments | 9.01M | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 143.52K | 228.87K | 674.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 429.72K | 121.47K | 0 | 0 | 0 |
| Total Current Assets | 30.6M | 25.17M | 14.91M | 34.44M | 85.1M |
| Property, Plant & Equipment (Net) | 589.07K | 718.61K | 343.52K | 424.92K | 987.13K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.37K | 3.37K | 5.2K | 80.76K | 64.33K |
| Total Non-current Assets | 620.44K | 721.98K | 348.72K | 505.68K | 1.05M |
| Total Assets | 31.22M | 25.89M | 15.26M | 34.94M | 86.15M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 94.92K | 107.53K | 7.83M | 0 | 78.31K |
| Tax Payables | 0 | 0 | 27.42K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.01K | 21.66K | 646.48K | 1.49M | (78.31K) |
| Total Current Liabilities | 2.27M | 4.14M | 14.59M | 3.1M | 5.63M |
| Long-term Debt | 9.7M | 11.92M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 9.84M | 11.99M | 0 | 0 | 75.91K |
| Total Liabilities | 12.1M | 16.13M | 14.59M | 3.1M | 5.7M |
| Common Stock | 77.65M | 96.13M | 69.96M | 116.36M | 195.41M |
| Retained Earnings | (74.26M) | (104.63M) | (79.43M) | (131M) | (169.58M) |
| Accumulated OCI | 16.56M | (3.77M) | (2.04M) | (4.16M) | (2.04M) |
| Other Stockholders Equity | 0 | (931) | 0 | 0 | 0 |
| Minority Interest | (833.84K) | (783.49K) | (996.78K) | (1.57M) | (1.6M) |
| Total Equity | 19.12M | 9.76M | 671.86K | 31.84M | 80.45M |
| Total Debt | 9.99M | 12.17M | 7.87M | 71.86K | 154.36K |
| Net Debt | (10.9M) | (12.56M) | (6.69M) | (33.03M) | (80.41M) |
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Intrinsic Alpha fair value
Locked
Current Price
$6.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.